Vicore Pharma to Present at the European Respiratory Society Congress 2026

Vicore will present new data on the design and baseline characteristics of patients enrolled in the global Phase 2b ASPIRE trial in buloxibutid, the company’s lead program in idiopathic pulmonary fibrosis (IPF), along with translational findings on AT2 receptor activation in alveolar epithelial type II cells and its association with MMP-13, a collagenase linked to fibrosis resolution.

Oral presentation: ASPIRE-IPF, a global, double-blind, randomized, placebo-controlled Phase 2b trial of buloxibutid, an angiotensin II type 2 receptor agonist, in idiopathic pulmonary fibrosis: trial design and patient characteristics
Presenter: Toby Maher (Los Angeles, California, United States)
Presented within the session: Moving forward in interstitial lung disease: new data on novel therapies
Date: Monday, September 7, 2026
Presentation Time: 11:35 CEST

Poster: Buloxibutid (C21) activates the angiotensin II type 2 receptor in alveolar epithelial type II cells, increasing MMP-13 associated with fibrosis resolution in idiopathic pulmonary fibrosis
First author: Johan Raud (Stockholm, Sweden)
Presented within the Poster session: Metabolic pathways in pulmonary fibrosis
Date: Sunday, September 6, 2026
Presentation Time: 12:30 CEST

Following the presentations, the materials will be made available on the Publications page of Vicore’s website.

For further information, please contact:
Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma 
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com

About Idiopathic Pulmonary Fibrosis (IPF)
IPF is a progressive and lethal fibrotic lung disease impacting approximately 250,000 people across the United States and Europe. The average life expectancy following diagnosis is 3-5 years, and currently approved therapies only slow the decline of lung function. While there are three anti-fibrotic therapies available today, a large proportion of patients do not initiate treatment, and those who do often discontinue due to limited efficacy and significant tolerability issues. With a growing patient population, there is a clear need for new disease-modifying treatments.

About the Phase 2b ASPIRE Trial
ASPIRE is an ongoing global 52-week Phase 2b, randomized, double-blind, placebo-controlled clinical trial designed to assess the efficacy and safety of buloxibutid in IPF patients who are either not currently on treatment or are receiving standard of care (nintedanib or nerandomilast). Participants are randomized to receive one of two doses of buloxibutid (100 mg or 50 mg taken orally twice daily) or placebo. The primary endpoint is change from baseline in forced vital capacity (FVC) at 52 weeks, the registrational endpoint for IPF. Secondary endpoints include safety, tolerability, and the proportion of patients with disease progression over the trial period. The trial completed enrollment in April 2026, with more than 360 patients enrolled across over 100 sites in 14 countries, including the United States. Recruitment was completed ahead of schedule, positioning the company to report topline results in mid-2027.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements concerning Vicore Pharma, its leadership, its pipeline, and the development of buloxibutid. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks identified in the section entitled “Risk Factors” in Vicore Pharma’s filings with the U.S. Securities and Exchange Commission and discussed in Vicore Pharma’s Swedish filings, its press releases, and the Registration Statements. Forward-looking statements include, among others, anticipated presentations at the upcoming ERS Congress, the timing of topline results from the Phase 2b ASPIRE clinical trial, and the treatment potential of buloxibutid in IPF. Vicore Pharma cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Vicore Pharma disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Vicore Pharma’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.